MCID: PLY040
MIFTS: 34

Polymorphous Low-Grade Adenocarcinoma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Polymorphous Low-Grade Adenocarcinoma

MalaCards integrated aliases for Polymorphous Low-Grade Adenocarcinoma:

Name: Polymorphous Low-Grade Adenocarcinoma 52
Polymorphous Low Grade Adenocarcinoma 71

Classifications:



External Ids:

UMLS 71 C1266086

Summaries for Polymorphous Low-Grade Adenocarcinoma

MalaCards based summary : Polymorphous Low-Grade Adenocarcinoma, also known as polymorphous low grade adenocarcinoma, is related to rare tumor and adenocarcinoma. An important gene associated with Polymorphous Low-Grade Adenocarcinoma is CEACAM3 (CEA Cell Adhesion Molecule 3), and among its related pathways/superpathways are MicroRNAs in cancer and DNA Damage. The drugs Trastuzumab and Antineoplastic Agents, Immunological have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Polymorphous low-grade adenocarcinoma (PLGA) is a rare, asymptomatic, slow-growing malignant salivary... more...

Related Diseases for Polymorphous Low-Grade Adenocarcinoma

Diseases related to Polymorphous Low-Grade Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 240)
# Related Disease Score Top Affiliating Genes
1 rare tumor 31.1 KIT ACTC1
2 adenocarcinoma 31.1 NTRK3 MUC1 KIT CTNNB1 CCND1
3 adenoma 30.7 MUC1 MKI67 LGALS3 CTNNB1 CCND1
4 papillary adenocarcinoma 30.5 VIM MUC1 CEACAM3
5 cystadenocarcinoma 30.3 VIM MUC1 CEACAM3 ACTC1
6 myoepithelial carcinoma 30.2 VIM S100A1 MUC1 ACTC1
7 epithelial-myoepithelial carcinoma 30.2 VIM TP63 MUC1 ACTC1
8 salivary gland carcinoma 30.1 NTRK3 NFIB KIT
9 non-functioning pituitary adenoma 30.1 S100B MUC1
10 mucoepidermoid carcinoma 29.8 TP63 S100A1 MUC1 MKI67 CCND1 ACTC1
11 squamous cell carcinoma 29.6 TP63 MUC1 MKI67 CTNNB1 CCND1
12 pleomorphic adenoma 28.7 VIM TP63 SERPINB5 S100B S100A1 MYH11
13 myoepithelioma 28.6 VIM TP63 SERPINB5 S100B S100A1 MUC1
14 gastrointestinal stromal tumor 27.3 VIM S100B S100A1 NTRK3 MYH11 MKI67
15 adenoid cystic carcinoma 26.4 VIM TP63 SERPINB5 S100B S100A1 NTRK3
16 axillary lipoma 10.5 MUC1 KIT
17 ovarian fibrothecoma 10.5 KIT ACTC1
18 lymphangiectasis 10.5 VIM ACTC1
19 hard palate cancer 10.5
20 intravascular papillary endothelial hyperplasia 10.5 VIM ACTC1
21 nodular hidradenoma 10.5 VIM MUC1
22 testicular gonadoblastoma 10.5 VIM KIT
23 glomangiomyoma 10.5 VIM ACTC1
24 endometrial mucinous adenocarcinoma 10.5 VIM MUC1
25 pancreatic foamy gland adenocarcinoma 10.5 MUC1 CCND1
26 lipoadenoma 10.5 TP63 MUC1
27 benign metastasizing leiomyoma 10.5 VIM ACTC1
28 liver fibroma 10.4 VIM KIT
29 senile angioma 10.4 VIM KIT
30 angiolipoma 10.4 VIM ACTC1
31 mast-cell sarcoma 10.4 VIM KIT
32 limbal stem cell deficiency 10.4 TP63 MUC1
33 hepatoid adenocarcinoma 10.4 MUC1 CEACAM3
34 microcystic stromal tumor 10.4 CTNNB1 CCND1
35 spindle cell lipoma 10.4 VIM ACTC1
36 extraskeletal ewing sarcoma 10.4 VIM MUC1
37 bladder leiomyoma 10.4 VIM KIT
38 polycystic liver disease 1 with or without kidney cysts 10.4 MUC1 CEACAM3 ACTC1
39 desmoplastic small round cell tumor 10.4 VIM MUC1
40 biphasic synovial sarcoma 10.4 VIM MUC1
41 trachea adenoid cystic carcinoma 10.4 MYB KIT
42 bile duct adenoma 10.4 VIM MUC1 CEACAM3
43 apocrine adenocarcinoma 10.4 MUC1 CEACAM3
44 metanephric adenoma 10.4 VIM MUC1 CEACAM3
45 granulosa cell tumor of the ovary 10.4 VIM CEACAM3 ACTC1
46 sarcomatoid renal cell carcinoma 10.4 S100A1 MUC1 KIT
47 histiocytoma 10.3 VIM KIT ACTC1
48 epithelioid leiomyosarcoma 10.3 VIM MUC1 ACTC1
49 nephrogenic adenoma 10.3 TP63 S100A1 MUC1
50 papillary tumor of the pineal region 10.3 VIM S100A1 MUC1

Graphical network of the top 20 diseases related to Polymorphous Low-Grade Adenocarcinoma:



Diseases related to Polymorphous Low-Grade Adenocarcinoma

Symptoms & Phenotypes for Polymorphous Low-Grade Adenocarcinoma

GenomeRNAi Phenotypes related to Polymorphous Low-Grade Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10 MYB
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10 NFIB VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10 NFIB
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10 MYB
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10 MYB
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10 MYB
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10 CCND1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-144 10 NFIB
10 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10 VIM
11 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10 MYB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10 CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10 MYB
15 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10 MYB
17 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10 MYB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10 CCND1 CTNNB1 MYB NFIB VIM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10 CTNNB1 MYB
23 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10 CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10 CCND1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10 CCND1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10 CCND1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10 CCND1 NFIB
29 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10 VIM
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10 VIM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10 NFIB
32 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10 CTNNB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10 CTNNB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10 VIM
36 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10 CTNNB1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10 CTNNB1 MYB
38 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10 CTNNB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10 MYB
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10 VIM
41 Decreased viability in esophageal squamous lineage GR00235-A 9.61 CCND1 CEACAM3 CTNNB1 KIT MYB NFIB

MGI Mouse Phenotypes related to Polymorphous Low-Grade Adenocarcinoma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 ACTC1 CCND1 CTNNB1 KIT LGALS3 MYB
2 cellular MP:0005384 10.2 ACTC1 CCND1 CTNNB1 KIT LGALS3 MYB
3 behavior/neurological MP:0005386 10.19 CCND1 CTNNB1 KIT LGALS3 NTRK3 S100A1
4 growth/size/body region MP:0005378 10.14 ACTC1 CCND1 CTNNB1 KIT LGALS3 MYB
5 mortality/aging MP:0010768 10.1 ACTC1 CCND1 CTNNB1 KIT LGALS3 MYB
6 digestive/alimentary MP:0005381 9.98 CCND1 CTNNB1 KIT LGALS3 MYH11 NFIB
7 integument MP:0010771 9.97 CCND1 CTNNB1 KIT LGALS3 MYB MYH11
8 muscle MP:0005369 9.8 ACTC1 CTNNB1 KIT MYH11 S100A1 TP63
9 no phenotypic analysis MP:0003012 9.7 CTNNB1 KIT MKI67 MYB NTRK3 SERPINB5
10 normal MP:0002873 9.7 ACTC1 CCND1 CTNNB1 KIT MKI67 MYB
11 respiratory system MP:0005388 9.32 CCND1 CTNNB1 KIT LGALS3 MYH11 NFIB

Drugs & Therapeutics for Polymorphous Low-Grade Adenocarcinoma

Drugs for Polymorphous Low-Grade Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
2 Antineoplastic Agents, Immunological Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab

Search NIH Clinical Center for Polymorphous Low-Grade Adenocarcinoma

Genetic Tests for Polymorphous Low-Grade Adenocarcinoma

Anatomical Context for Polymorphous Low-Grade Adenocarcinoma

MalaCards organs/tissues related to Polymorphous Low-Grade Adenocarcinoma:

40
Salivary Gland, Breast, Lung, Bone, Pituitary, Ovary, Myeloid

Publications for Polymorphous Low-Grade Adenocarcinoma

Articles related to Polymorphous Low-Grade Adenocarcinoma:

(show top 50) (show all 330)
# Title Authors PMID Year
1
Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: Incidence and outcomes by site and histological type. 61
31174233 2019
2
Historical Evolution of the Polymorphous Adenocarcinoma. 61
30187348 2019
3
Polymorphous adenocarcinoma: an overview of immunohistochemical features and insights on molecular pathology. 61
30723885 2019
4
Polymorphous Low-Grade Adenocarcinoma: A Proposed Reconstruction Protocol Based on Past Surgical Experience. 61
30817510 2019
5
Immunohistochemical evaluation of salivary gland tumors differentiation and proliferation by using calponin and telomerase. 61
30705574 2019
6
Expression of α-smooth muscle actin in benign and malignant salivary gland tumors: An immunohistochemical study. 61
30303133 2018
7
Polymorphous adenocarcinoma of the salivary glands: reappraisal and update. 61
29761209 2018
8
Immunohistochemical Expression of CD-117 (c-KIT), P-53 and Ki-67 in Adenoid Cystic Carcinoma of Palate. 61
29866247 2018
9
Immunohistochemical study of salivary gland tumors in a tertiary institution in South-South Region of Nigeria. 61
30158766 2018
10
The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. 61
29266837 2018
11
The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas. 61
29076877 2018
12
Diagnostic utility of C-kit protein (CD117) expression in differentiating adenoid cystic carcinoma and polymorphous low grade Adenocarcinoma. 61
29492062 2017
13
Advancing toward a molecular characterization of polymorphous low grade adenocarcinoma. 61
28939261 2017
14
Expression of C-X-C motif chemokine receptors 4 and 7 in salivary gland neoplasms. 61
28772134 2017
15
Polymorphous Low Grade Adenocarcinoma of Hard Palate: AHistopathological Pictorial. 61
29056135 2017
16
Establishment of a primary culture of polymorphous low grade adenocarcinoma cells. 61
28647648 2017
17
Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. 61
28961851 2017
18
Polymorphous Low Grade Adenocarcinoma of the Parotid in a Teenager. 61
28955679 2017
19
Newly Described Entities in Salivary Gland Pathology. 61
28614209 2017
20
Histologic and immunohistochemical identification of cribriform adenocarcinoma. 61
28610739 2017
21
Parotid gland tumors. Results of retrospective analysis of 149 patients treated at the Clinical Department of Cranio-Maxillofacial Surgery, Clinic of Otolaryngology and Oncologic Laryngology of Military Institute of Medicine in Warsaw in years 2006-2016. 61
28541244 2017
22
Cribriform adenocarcinoma of the minor salivary gland arising in the tonsil with metastasis to a cervical lymph node: A case report with description of fine needle aspiration cytology. 61
28205384 2017
23
Cribriform adenocarcinoma of the soft palate with multiple lymph node metastasis and long-term follow-up. 61
28094218 2017
24
Factors that may influence polymorphous low-grade adenocarcinoma growth. 61
28188441 2017
25
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Oropharynx. 61
28247229 2017
26
Mammaglobin and DOG-1 expression in polymorphous low-grade adenocarcinoma: an appraisal of its origin and morphology. 61
27591391 2017
27
Salivary Gland Tumors: Current Concepts and Controversies. 61
28153132 2017
28
Newly described salivary gland tumors. 61
28060365 2017
29
Basaloid/blue salivary gland tumors. 61
28060371 2017
30
Sclerosing Microcystic Adenocarcinoma of the Head and Neck Mucosa: A Neoplasm Closely Resembling Microcystic Adnexal Carcinoma. 61
27233253 2016
31
Lysozyme Expression Can be Useful to Distinguish Mammary Analog Secretory Carcinoma from Acinic Cell Carcinoma of Salivary Glands. 61
27177644 2016
32
Predictors of Outcome in the Phenotypic Spectrum of Polymorphous Low-grade Adenocarcinoma (PLGA) and Cribriform Adenocarcinoma of Salivary Gland (CASG): A Retrospective Study of 69 Patients. 61
27454943 2016
33
Cribriform adenocarcinoma of minor salivary gland: A mimic of polymorphous low-grade adenocarcinoma. 61
27721624 2016
34
Immunoexpression of growth factors and receptors in polymorphous low-grade adenocarcinoma. 61
26671844 2016
35
Comparison of p63 and p40 (ΔNp63) as Basal, Squamoid, and Myoepithelial Markers in Salivary Gland Tumors. 61
26230372 2016
36
Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland. 61
26426580 2016
37
Doing more with less: the challenging diagnosis of polymorphous low-grade adenocarcinoma in incisional biopsy samples. 61
26408830 2016
38
Plasmacytoid-Type Cellular Differentiation in Polymorphous Low-Grade Adenocarcinoma. 61
26912473 2016
39
Multiportal combined transnasal transoral transpharyngeal endoscopic approach for selected skull base cancers. 61
26855345 2016
40
Polymorphous low-grade adenocarcinoma of the epiglottis: A case report. 61
27123278 2016
41
Polymorphous low-grade adenocarcinoma: A Danish national study. 61
27016011 2016
42
Giant cribriform adenocarcinoma of the tongue showing PRKD3 rearrangement. 61
27179279 2016
43
Clinical utility of myb rearrangement detection and p63/p40 immunophenotyping in the diagnosis of adenoid cystic carcinoma of minor salivary glands: a pilot study. 61
26711711 2016
44
Polymorphous Low-Grade Adenocarcinoma of the Palate: A Rare Case Report. 61
27366306 2016
45
Study of oral cavity lesions by infrared spectroscopy. 61
27049108 2016
46
Polymorphous Low-Grade Adenocarcinoma of the Oral Cavity. 61
26413969 2015
47
A clinicopathologic study of 1,047 cases of salivary gland tumors in Thailand. 61
25328924 2015
48
[Diagnostic value of MYB protein expression in adenoid cystic carcinoma and status of MYB gene copy number]. 61
26705183 2015
49
A case report of a pulmonary metastasis of a polymorphous low-grade adenocarcinoma. 61
25693921 2015
50
Polymorphous low-grade adenocarcinoma of the head and neck: A population-based study of 460 cases. 61
25877006 2015

Variations for Polymorphous Low-Grade Adenocarcinoma

Expression for Polymorphous Low-Grade Adenocarcinoma

Search GEO for disease gene expression data for Polymorphous Low-Grade Adenocarcinoma.

Pathways for Polymorphous Low-Grade Adenocarcinoma

Pathways related to Polymorphous Low-Grade Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.16 VIM TP63 SERPINB5 CCND1
2 12.09 VIM TP63 MKI67 CCND1
3 11.69 VIM LGALS3 CCND1
4 11.64 VIM MUC1 CCND1
5
Show member pathways
11.58 NTRK3 MYH11 CTNNB1 CCND1 ACTC1
6 11.22 MYB KIT CCND1
7 11 VIM MKI67 CTNNB1
8 10.37 S100B LGALS3

GO Terms for Polymorphous Low-Grade Adenocarcinoma

Biological processes related to Polymorphous Low-Grade Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.71 VIM MUC1 KIT CCND1
2 response to ethanol GO:0045471 9.65 NTRK3 CCND1 ACTC1
3 positive regulation of cell proliferation GO:0008284 9.65 S100B NTRK3 KIT CTNNB1 CCND1
4 positive regulation of MAPK cascade GO:0043410 9.63 NTRK3 KIT CTNNB1
5 positive regulation of histone H3-K4 methylation GO:0051571 9.43 MYB CTNNB1
6 negative regulation of transcription by RNA polymerase II GO:0000122 9.43 TP63 S100A1 NFIB MYB CTNNB1 CCND1
7 regulation of T cell proliferation GO:0042129 9.37 LGALS3 CTNNB1
8 positive regulation of phospholipase C activity GO:0010863 9.32 NTRK3 KIT
9 cranial skeletal system development GO:1904888 9.16 TP63 CTNNB1
10 positive regulation of gene expression GO:0010628 9.02 VIM NTRK3 KIT CTNNB1 ACTC1

Molecular functions related to Polymorphous Low-Grade Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 S100 protein binding GO:0044548 8.96 S100B S100A1
2 p53 binding GO:0002039 8.8 TP63 NTRK3 MUC1

Sources for Polymorphous Low-Grade Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....